| 1. |
|
|
| 2. |
- Axfors, Cathrine, et al.
(författare)
-
Association between convalescent plasma treatment and mortality in COVID-19 : a collaborative systematic review and meta-analysis of randomized clinical trials
- 2021
-
Ingår i: BMC Infectious Diseases. - : BioMed Central (BMC). - 1471-2334. ; 21:1
-
Forskningsöversikt (refereegranskat)abstract
- Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, ). Methods: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I-2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.
|
|
| 3. |
- Kehoe, Laura, et al.
(författare)
-
Make EU trade with Brazil sustainable
- 2019
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 364:6438, s. 341-
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
- Bollen, Math, et al.
(författare)
-
CIGRE/ CIRED/ UIE joint working group C4.110, Voltage dip immunity of equipment in installations : main contributions and conclusions
- 2009
-
Ingår i: CIRED 20th International Conference on Electricity Distribution. - Red Hook, NY : Curran Associates, Inc.. - 9781615675227
-
Konferensbidrag (refereegranskat)abstract
- This paper presents the results from the work of joint working group C4.110: a cooperation between CIGRE, CIRED and UIE. Its mandate period stretches from early 2006 through early 2009. The group has addressed several aspects of the immunity of, especially, industrial equipment against voltage dips. Quantifying or specifying equipment performance is part of the assessment or improvement of the voltage-dip ride-through of an industrial process.
|
|
| 5. |
- Bollen, Math, et al.
(författare)
-
CIGRE/CIRED/UIE JWG C4.110 - Voltagedip immunity of equipment in installations : status April 2008
- 2008
-
Ingår i: 2008 13th International Conference on Harmonics and Quality of Power. - Piscataway, NJ : IEEE Communications Society. - 9781424417704
-
Konferensbidrag (refereegranskat)abstract
- This paper presents the status of the work, by April 2008, in C4.110, a joint working group by CIGRE, CIRED and UIE. The scope of the working group is to gather technical knowledge on the immunity of equipment, installations and processes against voltage dips, and to use this knowledge in the further development of methods and standards. The activities of the working group are divided in seven "chapters". Chapters 1 and 7 are introduction and conclusions, respectively. Chapter 2 gives a general description of voltage dips as they appear at the terminals of sensitive equipment. Chapter 3 describes the performance of equipment and processes during voltage dips. This chapter also includes recommendations on the design of processes. In Chapter 4 the results from Chapter 2 and Chapter 3 are combined to set requirements for the dip characteristics that should be included in immunity testing. Chapter 5 is the data gathering chapter, covering data on voltage-dip statistics at different locations, but also data on the economics of equipment immunity and testing. Finally, in Chapter 6, recommendations for immunity objectives will be given. Important contributions of the working group are: a check-list of voltage dip characteristics to be used early in the design of equipment; a methodology to assess the performance of a complete installation and to include voltage-dip performance in the design of the installation; recommendations for characterization testing of equipment against voltage dips; recommendations for voltagedip immunity of equipment.
|
|
| 6. |
|
|
| 7. |
|
|
